<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696952</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-207</org_study_id>
    <nct_id>NCT04696952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects</brief_title>
  <official_title>A Driving Performance Evaluation Study of TS-142 Using a Driving Simulator in Non-elderly and Elderly Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the residual effects of TS-142 on driving performance in healthy&#xD;
      and elderly subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP) evaluated by using a driving simulator on day 2</measure>
    <time_frame>On day 2 at 9 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP) evaluated by using a driving simulator on day 9</measure>
    <time_frame>On day 9 at 9 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received TS-142 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-142 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received TS-142 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zopiclone 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received Zopiclone 7.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142</intervention_name>
    <description>TS-142</description>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zopiclone</intervention_name>
    <description>Zopiclone</description>
    <arm_group_label>Zopiclone 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 21 years or older but less than 80 years at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  Those with a BMI of 18.5 or more and less than 25.0 and a body weight of 40.0 kg or&#xD;
             more at screening tests&#xD;
&#xD;
          -  Have an ordinary driving license and have driven on a daily basis for more than 3&#xD;
             years&#xD;
&#xD;
          -  Have a constant sleep pattern (waking up from 5:00 to 9:00, falling asleep from 21:00&#xD;
             to 1:00 and time in bed is from 6 to 8 hours)&#xD;
&#xD;
          -  No visual impairment (those who have &gt;=0.7 vision in both eyes and &gt;=0.3 in each eye&#xD;
             at vision test of screening tests, enable to correct the vision with eyeglasses or&#xD;
             contact lens)&#xD;
&#xD;
          -  Those who have cognitive and physical function (adequate dexterity of fingers, vision&#xD;
             and hearing etc.) to operate Driving Simulator (DS) certainly, understand and carry&#xD;
             out the direction on the task of the DS evaluation&#xD;
&#xD;
          -  Those with no abnormal findings in medical examinations, vital signs, or 12-lead&#xD;
             electrocardiogram and whose laboratory test results were within the reference values&#xD;
             of the study site based on the results of screening tests and tests obtained before&#xD;
             hospitalization of Visit 1&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have any disease and are not regarded as healthy subjects based on the&#xD;
             medical judgment of the principal investigator or sub-investigator&#xD;
&#xD;
          -  Those who have a medical history that makes them ineligible for participation in this&#xD;
             study such as respiratory disease, cardiovascular disease, gastrointestinal disease,&#xD;
             liver disorder, renal disorder, urological disease, endocrine disease, metabolic&#xD;
             disease, hematological disease, immune disease, skin disease, neurological disease,&#xD;
             mental disorder etc.&#xD;
&#xD;
          -  Those who have had symptoms of parasomnia (parasomnia, sleepwalking, abnormal dreams,&#xD;
             nightmares), narcolepsy-like symptoms (cataplexy, hypnagogic hallucinations, sleep&#xD;
             paralysis), or suicide attempt&#xD;
&#xD;
          -  Those who have hypersensitivity to zopiclone or s-zopiclone&#xD;
&#xD;
          -  Those who have experienced a time difference of 6 hours or more within 1 week prior to&#xD;
             Visit 1, or who will be exposed to such time difference during the study period&#xD;
&#xD;
          -  Those who have performed irregular shift work or night shift work within 4 weeks prior&#xD;
             to Visit 1, or need to do so during the study period&#xD;
&#xD;
          -  Those who have performed the DS evaluation used in this clinical trial in the past&#xD;
&#xD;
          -  Those who received TS-142 (active drug) in the past&#xD;
&#xD;
          -  Those who go of course even once at the DS evaluation in Visit1&#xD;
&#xD;
          -  Those whose total SDLP in 60 minutes at the DS evaluation in Visit1 is more than 60 cm&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1413</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

